Revista Peruana de Reumatología: Volumen 2 Nº 2, Año 1996 LIMA-PERÚ

BIBLIOGRAFÍA

1. Rico: Historia de la osteoporosis, en RICO II edición: El síndrome osteoporético. Sandoz-Venezuela 1988; 33.

2. Albrigth, F. Postmenopausal osteoporosis. Trans. Assoc. Am. Phys. 1940; 55: 298.

3. Christiansen, C. Consensus Development Conference on Osteoporosis. Am J Of Med. 1993; 95 (suppl 5A): 5A-1s.

4. Demester DW. Patogenie de la osteoporosis. The Lancet 1993; 341: 797-801.

5. Cooper, C. Hip fractures in the enderly: a world mide proyection. Osteoporosis Int. 1992; 2: 285-89.

6. Burckhardt, DE. The role of calcium intake in the constitution of peak mass. Rev. Clin. Esp. 1991; 188-1: 44.

7. Lufkin, E. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann. of Med. Int. 1992; 117: 1-9.

8. Watts, N. Intermittent cyclical etidronate treatment of post menopausal osteoporosis. New. Eng. J. Med. 1990; 323: 73.

9. Burckhardt, DE. Treatment of osteoporosis. Current Opinion of Rheum. 1992; 4: 402-409.

10. Chapuy, M. Vitamina D3 and calcium to prevent hip fractures in enderly women. New. Eng. J. Med. 1992; 327: 1637-42

11. Reginster JY. Calcitonina for prevention and treatment of osteoporosis. Am J Of Med. 1993; 95: (suppl-5a), 44s-7s.

12. Acevedo, E. Osteoporosis. Revista Médica IPSS. 1994; Vol. 3,2: 41-50.

13. Robles E, Pastor C. Calcitonina en osteoporosis postmenopáusica. Libro de Resúmenes del XII Congreso Bolivariano y III Congreso Peruano de Reumatología. Lima 1984.

14. Punnk K. Analgesic effect of intranasal salmon calcitonin in treatment of osteoporosis vertebral fracture. Clin. Ther. 1989; 11: 205-9.

15. Kanis J. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Br. Med. J. 1992; 305: 1124-8.

16. Rico H. Salmon Calcitonin reduce vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 1992; 16: 131-8.

17. Pumarino, H. Osteoporosis, Sandoz Farmacéutica Lmta. Chile. 1992; Pagina 10.

18. Coop D. et al. Direct humoral control of parathyroid function in the dog. Proc. Soc. Exp Biol Med. 1961; 107: 342-4.

19. Chambers, T. Pharmacological control of osteoclastic motility. Calcif. Tissues Int. 1983; 35: 566-79.

20. Feldman R. Effects of parathyroid hormone and calcitonin on ostyeoclast formation in vitro Endocri. 1980; 107: 1137-43.

21. Cannigia A. Calcium metabolism and 47-calcium kinetica before and after long term thyrocalcitonin treatment in senile osteoporosis. Clinic. Scl. 1970; 38: 397-407.

22. Milhaud G. Calcitonin treatment of postmenopausal osteoporosis, evaluation of efficacy by principal component analysis Biomedicine. 1975; 23: 223-2.

23. Lyritis A. Analgesic effect of salmon calcitonin in osteoporosis vertebral fractures: a double blind placebo controlled clinical study. Calcif. Tiss Int 1991; 49: 369-72.

24. Ljunghall, S. Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled double blind study. Calci. Tissue Int. 1991; 49: 179.

25. Guidobono F. Anticonceptive activity of cel calcitonin, injected into the inflamed paw in rate. Neuropharmacology. 1991; 30: 1275-8.

26. Gherdini C. Calcitonin and analgesic. Sandoz Public. 1992.

27. Reginster J. An year controlled randomized trial of early post menopausal bone loss by intranasal calcitonin, Lancet. 1987; 1481-3.

28. Budin T. The effect of rectal and nasal administration of salmón calcitonin in normal subjects. Calcific. Tissues Int. 1987; 41: 245-7.

29. Overgaard, K. Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose response study. Br. Med. J. 1992; 305: 556-61.

Regresar al Artículo